{
    "title": "103_hr1926",
    "content": "The Act titled \"National Narcotics Leadership Act Amendments of 1993\" implements the National Drug Control Strategy. The National Narcotics Leadership Act of 1988 is amended to allow the Director to require funding requests for specific initiatives in the budget submission to the Office of Management and Budget by National Drug Control Program agencies. SEC. 3. REPORT ON REPROGRAMMING; OFFICE PERSONNEL RESTRICTION. The Director must report quarterly to Congress on the need for reprogramming funds over $5,000,000 for National Drug Control Program activities. Additionally, a prohibition on political campaigning is imposed on Federal officers in the Office of National Drug Control Policy. The National Narcotics Leadership Act of 1988 prohibits Federal officers in the Office of National Drug Control Policy from participating in Federal election campaign activities, except for making contributions to individual candidates. SEC. 4. NATIONAL DRUG CONTROL STRATEGY OUTCOME MEASURES. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy, focusing on reduction of drug use and assessment of drug prevalence and frequency. The evaluation of Federal drug control effectiveness in the National Drug Control Strategy includes assessing the reduction of drug use among high-risk populations through national, State, and local surveys. Assessment of illicit drug use through national, State, and local surveys, focusing on high-risk populations and drug availability measures. Assessment of drug availability by measuring quantities of cocaine, heroin, and marijuana in the US, amount of drugs entering the country, and cultivation of poppy and coca plants. The assessment includes measuring the quantities of cocaine, heroin, and marijuana available in the United States, the amount of drugs entering the country, cultivation of poppy and coca plants, seized metric tons of heroin and cocaine, destroyed cocaine processing labs, and changes in the price and purity of heroin and cocaine. The assessment also includes measuring the effectiveness of Federal technology programs in improving drug detection and the amount and type of controlled substances diverted from legitimate sources. The assessment includes measuring the reduction of consequences of drug use and availability, estimating burdens drug users place on hospitals. The technology programs aim to improve drug detection capabilities at US ports of entry and assess the reduction of consequences of drug use, including burdens on hospital emergency rooms and national healthcare costs. The text discusses the impact of drug use on emergency rooms in the United States, including the costs associated with drug-related services, healthcare expenses, crime, and the contribution of drugs to the underground economy. The curr_chunk discusses the impact of drug use on public health, crime rates, and the underground economy in the United States. It also evaluates the status of drug treatment capacity within each state. The curr_chunk focuses on assessing the drug treatment capacity in the United States, including public and private treatment availability within each state, the number of treatment slots, and the accessibility of treatment on demand. The assessment of drug treatment capacity in the United States includes data on treatment slots available, accessibility for intravenous drug users and pregnant women, estimated number of drug users who could benefit from treatment, and the success of drug treatment programs. The assessment includes data on treatment slots availability, accessibility for intravenous drug users and pregnant women, estimated number of drug users who could benefit from treatment, and the success of drug treatment programs. The Director will assess the effectiveness of mechanisms federally and within each State to determine the quality of substance abuse treatment programs, qualifications of personnel, and patient admission to appropriate treatment settings. This assessment will be included in the National Drug Control Strategy submitted every second year. The Director will assess the quality of drug use measurement instruments and techniques, as well as the coverage of existing national drug use measurement instruments in the National Drug Control Strategy submitted every second year. The Director will assess current drug use measurement instruments and techniques, coverage of existing national drug use measurement instruments, and take corrective actions as needed. The Director will assess drug use measurement instruments, identify deficiencies, and propose remedies to improve treatment availability. The Director will identify factors restricting treatment availability and propose remedies. Federal agencies must cooperate to provide drug-related information. The Director shall report on drug use and availability in the US, including program effectiveness, with each National Drug Control Strategy. Federal agencies must cooperate to provide necessary drug-related information. The Director will report to the President and Congress on the assessment of drug use and availability in the US, including the effectiveness of various programs in reducing drug use and availability. SEC. 5 amends title 50, United States Code, to include the Director of the Office of National Drug Control Policy as a member of the National Security Council. SEC. 6 establishes the Counter-Drug Technology Assessment Center. The amendment to the National Narcotics Leadership Act of 1988 includes identifying and supporting the application of technology for drug treatment effectiveness. The amendment to the National Narcotics Leadership Act of 1988 involves providing assistance and support to the Office of National Drug Control Policy through the application of technology for drug treatment effectiveness. The National Narcotics Leadership Act of 1988 is amended to provide assistance and support to the Office of National Drug Control Policy. The National Narcotics Leadership Act of 1988 is amended to repeal and redesignate certain sections, including moving section 1003A to follow section 1007. SEC. 7 amends the National Narcotics Leadership Act to allow the Director to pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8 authorizes appropriations as needed for fiscal year 1994. SEC. 8 authorizes appropriations as needed for fiscal year 1994. SEC. 9 terminates the Office of National Drug Control Policy on September 30, 1994. Section 1009 of the National Narcotics Leadership Act of 1988 is amended to change the date from \"the date which is 5 years after the date of the enactment of this subtitle\" to \"September 30, 1994.\" This amendment was passed by the House of Representatives on November 21, 1993."
}